Waystar Holding Corp.WAY

Waystar Holding Corp. reported $313.9 million in revenue for the quarter ending 31 March 2026, alongside $43.3 million in net income and $0.22 in diluted earnings per share, all filed in its latest 10-Q. The company’s balance sheet shows $5.84 billion in assets against $1.90 billion in liabilities, leaving $3.94 billion in shareholders’ equity, but the real story is the $34.3 million of cash and equivalents on hand-thin enough that the glossy Innovation Lab™ brochures about autonomous RCM feel like they’re being underwritten by cash flow rather than cash in the bank.

Waystar sells patient billing software and revenue cycle management services to healthcare providers, including fertility clinics, positioning itself as a one-stop platform that promises to simplify workflows and bring in more revenue with fewer resources. The company’s marketing rails describe AI-powered autonomous RCM, early adopter programs, and fertility-specific financial care tools, all aimed at clinics juggling high-cost services and low insurance coverage. The public story is sleek; the filing evidence is less so.

Filed numbers for the quarter show revenue of $313.9 million, operating income of $80.5 million, and net income of $43.3 million. Diluted earnings per share came in at $0.22 on 195.2 million diluted shares outstanding. Operating cash flow clocked in at $84.9 million, while research and development spending hit $18.4 million. The company’s cash balance stood at $34.3 million, with total assets at $5.84 billion and liabilities at $1.90 billion, giving shareholders’ equity of $3.94 billion. The filing period is the three months ended 31 March 2026, and all figures are drawn directly from the 10-Q.

The company’s investor-relations rail points to patient billing services for physicians and specialty practices, an Innovation Lab™ touting AI-powered RCM, and an early adopter program inviting clinics to shape future product development. These are real product pages and releases, not filings, and they describe capabilities rather than financial outcomes. The Innovation Lab™ page promises to surface issues before billing and reduce rework, while the early adopter program frames participants as elite partners in product development-language that sells promise, not performance. The fertility-specific page promises true patient financial care, again positioning Waystar as a solution provider without disclosing how many fertility clinics actually pay for it. These are marketing materials, not revenue or adoption proofs.

Waystar’s share price has been a quiet spectator to a series of Form 4 filings in June and July, with insiders selling stock in small, orderly ranges between $23.00 and $23.27. The sales are disclosed in multiple filings, including a 17 July Form 4 and several on 9 June, all filed on SEC EDGAR. These are not block trades or panic dumps; they’re methodical unloadings that read like liquidity events rather than signalling. The company’s shareholder base and trading volumes are not disclosed in the filings collected here, so market mechanism observations would require additional source rails beyond the current evidence set.

The tension in the file is simple: Waystar’s public story is a glistening platform of AI and autonomous RCM, while the balance sheet reveals a company that is profitable and cash-generative but thin on liquidity. The operating cash flow is strong enough to fund R&D and still leave room for other uses, but the cash balance itself is modest. The company’s product pages and innovation pitches read like a future that doesn’t yet show up in the cash line. The next filing that would deepen the story would be a 10-K or updated 10-Q with segment-level revenue, customer counts, or cash flow detail beyond the headline numbers already provided.